

RECEIVED
CENTRAL FAX CENTER

JAN 11 2006

Fax

To: Mr. Everett White

From: Deanna J. Nelson, Ph.D.

Primary Examiner, Group Art Unit 1623

U.S. Patent & Trademark Office

Fax: 571-273-8300

Pages: 27 (including cover page)

Phone: 571-272-0660

Date: 1/11/2006

Re: Response to Office Action (Confirmation No. 3265)

☐ **Urgent** ☒ **For Review** ☐ **Please Comment** ☐ **Please Reply** ☐ **Please Recycle**

This document contains confidential information. The information is intended only for the use of the individual(s) named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or the taking of any action in reliance of the contents is strictly prohibited. Sender is not liable for any distribution or publication of this information by the recipient. If you have received this electronic mail in error, please notify the sender immediately at the number listed above.

RECEIVED
CENTRAL FAX CENTER

JAN 11 2006

Application No.	Filing Date	First Named Inventor	Attorney Docket No.	Responsive to Confirmation No.
10/688,585	10/18/2003	Deanna Jean Nelson	BLS21102	3265

104 TASMAN COURT, • 919-345-0339 • Fax 919-462.8767 • E-mail: biolink_life@yahoo.com
CARY, NC 27513

11 January 2006

Mr. Everett White
Primary Examiner, Group Art Unit 1623
US Patent and Trademark Office
PO Box 1450
Alexandria, VA 22313-1450

Transmitted by facsimile to 571-273-8300 on 11 January 2006

Dear Mr. White:

RE: Application No. 10/688,585
Filing Date: 10/18/2003
First Named Applicant: Deanna Jean Nelson
Title: Aminosalicylate Derivatives for Treatment of Inflammatory Bowel Disease


Responsive to the Office Action of 13 September 2005, for which a shortened statutory period for reply was set to expire three months from the mailing date of the communication. Claims 1-18 are pending in this application. Claims 8 and 11 are allowed. Claims 1-7, 9, 10, and 13-18 are rejected. Claim 12 is objected to.

Applicant respectfully petitions for a 1-month extension of time under 37 CFR 1.136(a) for filing a reply to the Office Action. A completed USPTO form "Petition for Extension of Time" and fee are enclosed with this submission.

Page 1 of 24

Affirmations

The Examiner has affirmed that prior art of record does not teach or fairly suggest a therapeutic 5-aminosalicylic acid derivative composition having the general formula:



wherein R is a poly(ethylene glycol) chain-containing residue having the general formula

$-\text{CH}_2\text{CH}_2\text{CH}_2-(\text{CH}_2\text{CH}_2\text{O})_n-\text{R}_1$, R_1 is H or a linear or branched lower alkyl group having from one to about 6 carbons, and n is a positive integer from about 3 to about 20.